PGx for Anticoagulant Drug

Scheme introduction

By detecting genes related to anticoagulants, analyze the gene types and gene defects contained in patients and whether their expression function is normal, assist doctors to develop individualized drug treatment plans for patients, and achieve predictable and accurate personalized medication, in order to achieve high efficiency and low toxicity treatment purposes.

Genetic polymorphism of CYP2C19 enzyme causes significant differences in enzyme activity among different individuals, which affects the therapeutic effect of clopidogrel, omeprazole, fluoxetine, phenobarbital and other drugs. According to the genotype of CYP2C19, the metabolic type of patients can be determined, and the dose can be adjusted reasonably, so as to realize individualized medication and reduce the toxic side effects.

Clopidogrel is a common drug used in the prevention and treatment of heart, brain and arterial circulation disorders caused by platelet aggregation in patients with coronary heart disease, thrombosis, and heart stent surgery.

The FDA added a boxed warning about poor metabolism to Clopidogrel's drug label, emphasizing the importance of testing for the CYP2C19 gene in these patients.

Gene detection of anticoagulant drugs